Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Individuals with cystic fibrosis (CF) require higher dosages of aminoglycosides due to an increased volume of distribution (V<sub>d</sub>) and clearance. Optimal dosing of aminoglycosides in the CF population is essential as repeated exposure to aminoglycosides during acute pulmonary exacerbations increases risk of nephrotoxicity and ototoxicity. To date, no studies have evaluated whether chronic CFTR modulator therapy affects pharmacokinetics of aminoglycoside antibiotics in CF patients. The objective of this study was to determine if the addition of a CFTR modulator affects elimination rate (K<sub>e</sub>) for intravenously administered tobramycin in the pediatric CF population. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This retrospective study included patients aged 2 to 18 years with CF receiving chronic therapy with a CFTR modulator. Patients included had an admission both pre‐ and post‐chronic CFTR modulator therapy during which they received therapy with IV tobramycin.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Thirty‐four patients were included in the study. The median time between pre‐ and post‐modulator admissions was 16.5 (13.8) months. Duration of CFTR modulator therapy prior to post‐modulator admission was a median of 8 (10.3) months. There was no significant difference in K<sub>e</sub> (hr<sup>‐1</sup>) between pre‐ and post‐modulator therapy, 0.41(0.21) pre and 0.39(0.09) post (p=0.5). V<sub>d</sub> and peak concentration were similar between both groups. There was no difference in nephrotoxicity as defined by the pRIFLE criteria (p=0.25). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>The pharmacokinetic parameters of intravenously administered tobramycin during admission for acute pulmonary exacerbation do not appear to change significantly after initiating chronic therapy with a CFTR modulator. Empiric dose adjustments for patients on CFTR modulators are not recommended.</p><p>This article is protected by copyright. All rights reserved.</p></section>

Effects of CFTR modulators on pharmacokinetics of tobramycin during acute pulmonary exacerbations in the pediatric cystic fibrosis population

A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation

Evaluation of Target Attainment for Tobramycin in Children and Adults with Cystic Fibrosis

Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis

Outcomes of Modulator Therapy Discontinued After Short‐Term Use in Adult Cystic Fibrosis

Population Pharmacokinetic Modeling of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Cystic Fibrosis

A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment

Effects of highly effective modulator therapy on the dynamics of the respiratory mucosal environment and inflammatory response in cystic fibrosis

Persistence and evolution of Pseudomonas aeruginosa following initiation of highly effective modulator therapy in cystic fibrosis

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Respiratory Outcomes of Interrupted Modulator Therapies in Children With Cystic Fibrosis

Tobramycin reduces key virulence determinants in the proteome of Pseudomonas aeruginosa outer membrane vesicles

Changes in Pulmonary Function and Controlled Ventilation-High Resolution CT of Chest After Antibiotic Therapy in Infants and Young Children with Cystic Fibrosis

Systemic effects of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the blood proteome

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform

Pharmacological Improvement of CFTR Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis

Impact of CFTR Modulator Therapies on Liver Function in Cystic Fibrosis Patients: A Systematic Review of Hepatic Biomarkers

A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis

Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections

Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis